



## CLINICAL PRACTICE

## Lp(a) and coronary disease: Rules of engagement – when to measure and how to treat

R Jayasinghe, K M Kostner

Lipoprotein (a) (Lp(a)) has been described as an important component of the lipid profile and a significant coronary risk factor when elevated. Controversy surrounds the importance of this lipoprotein variant, and its management is often challenging for clinicians. Important issues relate to the control and management of high Lp(a) levels, especially in patients at intermediate risk of cardiovascular disease. Clear guidelines are lacking on who needs Lp(a) measured, and when. We review practical points on investigating and managing Lp(a).

### Background

Lp(a) was first described in 1963 as a genetic variant of  $\beta$ -lipoproteins.<sup>1</sup> The physiological functions of Lp(a) remain a mystery. Most studies strongly suggest that it is an independent risk factor for cardiovascular disease.<sup>2</sup> A meta-analysis concluded that an increased plasma level of Lp(a) is an independent predictor of the presence of coronary artery disease (CAD), particularly in patients with hypercholesterolaemia.<sup>3</sup> The combination of high Lp(a) plasma concentrations and other cardiovascular risk factors, in particular low high-density lipoprotein (HDL), strongly increases the risk of CAD. In addition to containing significant amounts of cholesterol and being able to oxidise like low-density-lipoprotein (LDL), Lp(a) can exert antifibrinolytic actions, stimulate the proliferation of smooth-muscle cells, facilitate wound healing, act as an acute-phase reactant and generate bioactive derivatives that are retained in the vascular extracellular matrix. Lp(a) has been identified as the link between atherosclerosis and thrombosis. Stoichiometrically the

atherogenicity of Lp(a) is 10-fold that of LDL, though the latter dominates in the circulation. Lp(a) is also highly thrombogenic and bears structural resemblance to plasminogen, which explains its antifibrinolytic properties.<sup>4</sup>

### Coronary risk association

The plasma levels of oxidised phospholipids present in Lp(a) have been implicated in contributing to the atherogenicity of Lp(a),<sup>5</sup> which is a strong independent risk factor for CAD in various populations and ethnic groups.<sup>6</sup>

Lp(a) has a significant and well-described genetic heterogeneity. Its risk associations with vascular disease demonstrate racial and ethnic variations. Higher plasma concentrations are seen in blacks, postmenopausal women and people with hypercholesterolaemia. However, the strongest association with high Lp(a) levels and coronary disease is observed in middle-aged white men. High Lp(a) levels are associated with a high risk of stroke in blacks and in white women, but not in white men.<sup>7</sup>

Not all studies associate Lp(a) with increased coronary risk. The Physician's Health Study found no association between Lp(a) level and the risk of future ischaemic events,<sup>8</sup> but this observation could have been due to sampling and/or measurement errors. Some studies measured Lp(a) in long-term, frozen samples with insufficiently evaluated test kits. Moreover, owing to the wide range of plasma Lp(a) levels from less than 0.001 g/l to more than 3 g/l and the highly skewed distribution, studies that include small numbers of cases/controls are prone to random deviations.

### Measurement

Studies are sometimes controversial, as it is difficult to standardise the measurement of Lp(a) due to its heterogeneity. Recognition of the biological importance of apolipoprotein (a) (apo(a)) is also reflected by the International Standardization Committee, which recommends that the previous practice of reporting Lp(a) as a total mass be superseded by the measurement of Lp(a) protein either in terms of apo(a) or as apo(a) linked to apoB100.<sup>9</sup> In this way the level of Lp(a) cholesterol can be estimated by comparing it with that of LDL, important information to the clinician.

*R Jayasinghe, MB BS, PhD, FRACP, an interventional cardiologist, is Professor of Cardiology at Griffith University, Gold Coast, Australia, Professor of Medicine at Bond University, Gold Coast, and Director of Cardiology and Cardiovascular Services at Gold Coast Hospital.*

*K M Kostner, MB BS, PhD, FRACP, is a cardiologist at Mater Hospital, Brisbane, and Associate Professor of Medicine at the University of Queensland. He is an expert in cardiovascular prevention and lipidology.*

Corresponding author: R Jayasinghe (rohan\_jayasinghe@health.qld.gov.au)



## Investigation

'In whom should we measure Lp(a)?' remains to be the main question to be answered.

Serum levels of Lp(a) are genetically determined, with environmental factors having a negligible impact.<sup>10</sup> Childhood levels of Lp(a) are a better predictor and marker than any other lipoproteins for future CAD in young adult life.<sup>11</sup> Most lipidologists recommend a once-off measurement of Lp(a) in patients with vascular disease, especially in patients with premature cardiovascular disease and premature stroke, where other risk factors fail to explain the causation. Lp(a) is also useful in patients in the intermediate-risk group, according to the Framingham, Australian and New Zealand or Procarn risk calculators. If Lp(a) is elevated above 0.3 g/l in these patients, it is very important to treat their other risk factors, especially LDL, aggressively.

## Management

HMG-CoA (3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitors (statins) have no demonstrable efficacy in modifying Lp(a) levels. There are few means whereby plasma Lp(a) can be reduced, the most efficient therapeutic modalities known to selectively reduce plasma Lp(a) being Lp(a)-apheresis and nicotinic acid (Table I).

**Table I. Influence of drugs and other substances on plasma Lp(a) concentrations**

Substance	% decrease
Omega-3 fatty acids	5 - 20
Palm oil	10 - 25
Vegetarian diet	10
Nicotinic acid and derivatives	15 - 35
Aspirin	15 - 20
L-carnitine	10 - 15
Lp(a)/LDL apheresis	60 - 80
ACE inhibitors	10 - 40

Nicotinic acid and its derivatives can reduce Lp(a) levels by up to 35%.<sup>2</sup> All angiotensin-converting enzyme (ACE) inhibitors in monotherapy lower elevated Lp(a) plasma concentrations in proteinuric patients by reversing proteinuria and in turn reducing Lp(a) production by the liver.<sup>12</sup> Fosinopril seems to be the only ACE inhibitor to reduce Lp(a) concentrations in non-proteinuric patients as well, probably by increasing apo(a) fragmentation and excretion into the urine (Kostner K *et al.*, unpublished data).

The most effective therapy for lowering Lp(a) is extracorporeal elimination of Lp(a) with apheresis. LDL-apheresis and selective Lp(a)-apheresis using antibody-coupled columns, precipitation and complex formation at low pH, double filtration and direct absorption have been demonstrated to lower plasma Lp(a) to the same extent as LDL cholesterol (up to 80%).<sup>13</sup> However, these treatments are expensive and accessible only to a small number of high-risk patients. Most lipidologists and clinicians recommend lowering LDL cholesterol more aggressively to levels below 1.8 mmol/l when the Lp(a) level is above 0.3 g/l, even though hard evidence to merit this practice is lacking.

## Conclusion

Measurement of Lp(a) provides useful additional information about cardiovascular risk in patients with premature vascular disease and intermediate risk profiles. Aggressive LDL reduction and global coronary risk factor modulation are recommended in patients with elevated Lp(a). Coronary disease is an emerging major health challenge in Africa, with CAD projected to be the leading cause of death in Africa by 2030.<sup>14</sup> However, information on the role of Lp(a) as a coronary risk factor among developing communities, especially in Africa, is seriously lacking and more studies are required.

## References

1. Berg K. A new serum type system in man: the Lp system. *Acta Pathol Microbiol Scand* 1963; 59: 362-362.
2. Kostner KM, Kostner GM. Lipoprotein (a): Still an enigma? *Curr Opin Lipidol* 2002; 13(4): 391-396.
3. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary artery disease: meta-analysis of prospective studies. *Circulation* 2000; 102: 1082-1085.
4. Enas EA, Senthilkumar A. Coronary artery disease in Asian Indians: An update and review. *Int J Cardiol* 2001; 1: 2.
5. Tsimikas S, Brilakis ES, Miller ER, *et al.* Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 2005; 353(1): 46-57.
6. Sandholzer C, Halman D, Saha N, *et al.* Effect of apolipoprotein (a) polymorphism on the lipoprotein (a) concentration in seven ethnic groups. *Human Genet* 1991; 86: 607 - 614.
7. Ohira T, Schreiner PJ, Morrisett JD, *et al.* Lipoprotein(a) and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. *Stroke* 2006; 37(6): 1407-1412.
8. Ridker PM, Hennekens CA, Stampfer MJ. A prospective study of Lp(a) and the risk of myocardial infarction. *JAMA* 1993; 270: 2195-2199.
9. Marcovina S, Koschinsky ML, Albers J, *et al.* Report of the National Heart Lung and Blood Institute workshop on lipoprotein(a) and cardiovascular disease. Recent advances and future directions. *Clin Chem* 2003; 49: 1788-1796.
10. Dahlen CG. Lipoprotein(a) in cardiovascular disease: Review article and viewpoint. *Atherosclerosis* 1994; 108: 111-126.
11. Enas EA. Risk of primary and recurrent acute myocardial infarction from lipoprotein (a). *J Am Coll Cardiol* 1997; 29: 887-889.
12. Schlueter W, Keilani T, Battle DC. Metabolic effects of ACE inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril. *Am J Cardiol* 1993; 72(20): 37-44.
13. Hoffmann U, Derfler K, Haas M, *et al.* Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. *Am J Cardiol* 2003; 91: 461-464.
14. Mensah GA. Ischaemic heart disease in Africa. *Heart* 2008; 94: 836-884.